Vij, Vivian
Piayda, Kerstin
Nelles, Dominik
Gloekler, Steffen
Galea, Roberto
Fürholz, Monika
Meier, Bernhard
Valgimigli, Marco
O’Hara, Gilles
Arzamendi, Dabit
Agudelo, Victor
Asmarats, Lluis
Freixa, Xavier
Flores-Umanzor, Eduardo
De Backer, Ole
Sondergaard, Lars
Nombela-Franco, Luis
McInerney, Angela
Korsholm, Kasper
Nielsen-Kudsk, Jens Erik
Afzal, Shazia
Zeus, Tobias
Operhalski, Felix
Schmidt, Boris
Montalescot, Gilles
Guedeney, Paul
Iriart, Xavier
Miton, Noelie
Saw, Jacqueline
Gilhofer, Thomas
Fauchier, Laurent
Veliqi, Egzon
Meincke, Felix
Petri, Nils
Nordbeck, Peter
Ognerubov, Dmitrii
Merkulov, Evgeny
Cruz-González, Ignacio
Gonzalez-Ferreiro, Rocio
Bhatt, Deepak L.
Laricchia, Alessandra
Mangieri, Antonio
Omran, Heyder
Schrickel, Jan Wilko
Rodes-Cabau, Josep
Sievert, Horst
Nickenig, Georg
Sedaghat, Alexander http://orcid.org/0000-0001-7015-1056
Article History
Received: 16 March 2022
Accepted: 5 July 2022
First Online: 18 July 2022
Declarations
:
: Alexander Sedaghat has received travel grants from Abbott and Boston Scientific and is a proctor for Lifetech. Lars Sondergaard has received consultant fees and institutional research grants from Abbott and Boston Scientific, and is shareholder in Eclipse Medical. Dr Cruz-Gonzalez is a proctor for Abbott, Boston Scientific and Lifetech and was funded by ISCIII (PI19/00658) and co-funded by ERDF, "A way to make Europe". Jens Erik Nielsen-Kudsk is a proctor and consultant for Abbott and Boston Scientific. Dabit Arzamendi is a proctor for Abbott and Boston Scientific. Xavier Freixa is a proctor for Abbott, Boston Scientific and Lifetech. Antonio Mangieri is part of the advisory board of Boston Scientific and received an institutional grant from Boston Scientific. Dr. Nombela-Franco has served as a proctor of Abbott Vascular and received speaker honoraria from Boston Scientific and Abbott Vascular. Dr. Meier has received consultant fees from Abbott. Xavier Iriart is a proctor for Abbott and Boston Scientific. Dr. Deepak L. Bhatt discloses the following relationships - Advisory Board: AngioWave, Bayer, Boehringer Ingelheim, Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Regado Biosciences, Stasys; Board of Directors: AngioWave (stock options), Boston VA Research Institute, Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock), Society of Cardiovascular Patient Care, TobeSoft; Chair: Inaugural Chair, American Heart Association Quality Oversight Committee; Consultant: Broadview Ventures; Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial); Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees), Wiley (steering committee); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent.) Research Funding: Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio; Royalties: Elsevier (Editor, Braunwald’s Heart Disease); Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Takeda.